Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide

• US 6,906,169 B2
• Filed: 05/25/2001
• Issued: 06/14/2005
• Est. Priority Date: 05/25/2001
• Status: Expired due to Term

• Current Assignee: United Neuroscience Ltd. (Vaxxinity, Inc.)
• Original Assignee: United Biomedical, Inc.
• Inventors: Wang, Chang Yi
• Primary Examiner(s): TURNER, SHARON L
• Application Number:
  US09/865,294
• Publication Number:
  US 20030068325A1
• Time in Patent Office: 1,481 Days
• Field of Search: 530/300, 530/324, 530/326, 530/350, 530/403, 530/806, 530/810, 530/826
• US Class Current: 530/326
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 14/4711 Alzheimer's disease; Amyloid plaque core protein
• CPC Class Codes: Y10S 530/806 Antigenic peptides or proteins
• CPC Class Codes: Y10S 530/81 Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier

Abstract

The present invention relates to a composition comprsing a peptide immunogen useful for the prevention and treatment of Alzheimer'"'"'s Disease. More particularly, the peptide immunogen comprises a main functional/regulatory site, an N-terminal fragment of Amyloid β (Aβ) peptide linked to a helper T cell epitope (Th) having multiple class II MHC binding motifs. The peptide immunogen elicit a site-directed immune response against the main functional/regulatory site of the Aβ peptide and generate antibodies, which are highly cross-reactive to the soluble Aβ_1-42 peptide and the amyloid plaques formed in the brain of Alzheimer'"'"'s Disease patients. The antibodies elicited being cross reactive to the soluble Aβ_1-42 peptide, promote fibril disaggregation and inhibit fibrillar aggregation leading to immunoneutralization of the “soluble Aβ-derived toxins”; and being cross-reactive to the amyloid plaques, accelerate the clearance of these plaques from the brain. Thus, the composition of the invention comprising the peptide immunogen is useful for the prevention and treatment of Alzheimer'"'"'s Disease.

Claims

1. A peptide immunogen selected from the group consisting of SEQ ID NOs:

71, 72, 73, and 74.

2. A peptide immunogen of claim 1 consisting of SEQ ID NO:

73.

3. A peptide immunogen of claim 1 consisting of SEQ ID NO:

74.

4. A composition comprising a peptide immunogen of claim 1 and a pharmaceutically acceptable adjuvant and/or carrier selected from the group consisting of alum, liposyn, saponin, squalene, L121, emulsigen monophosphyryl lipid A (MPL), polysorbate 80, QS21, Montanide ISA51, ISA35, ISA206 and ISA 720.

5. A composition comprising a peptide immunogen of claim 2 and a pharmaceutically acceptable adjuvant and/or carrier selected from the group consisting of alum, liposyn, saponin, squalene, L121, emulsigen monophosphyryl lipid A (MPL), polysorbate 80, QS21, Montanide ISA51, ISA35, ISA206 and ISA 720.

6. A composition comprising a peptide immunogen of claim 3 and a pharmaceutically acceptable adjuvant and/or carrier selected from the group consisting of alum, liposyn, saponin, squalene, L121, emulsigen monophosphyryl lipid A (MPL), polysorbate 80, QS21, Montanide ISA51, ISA35, ISA206 and ISA 720.